Google
ARTV — ARTIVA BIOTHERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
ARTV FAQ
What is ARTV's ROE?
ARTIVA BIOTHERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -99.12%.
What is ARTV's dividend yield?
ARTIVA BIOTHERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is ARTV's Deepscope Quality Score?
Deepscope rates ARTV's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ARTV?
Deepscope's AI Timing Score for ARTV is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ARTV belong to?
ARTIVA BIOTHERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 8.54
Price
0.54
(6.75%)
Day Change
|
|
|---|
ARTV, ファンダメンタルスコアはnot good ( ファンダメンタル = 8) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.54 |
| PBV / Sector |
4.42 / 4.91
|
| Earning Per Share | -1.91 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
4.67 M
GREAT
|
| Average 1W Daily Value |
7.10 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:20 |
| Symbol | ARTV |
| Name | ARTIVA BIOTHERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 48.59 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 388.71 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5505 Morehouse Drive, San Diego, CA, United States, 92121
Phone: 858 267 4467
Website: https://www.artivabio.com
Employees: 104
Sector: Healthcare >> Biotechnology
Description: Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
